TY - JOUR
T1 - Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer
T2 - A multi-institutional study of AIRO—Head and Neck working group
AU - Orlandi, Ester
AU - Bonomo, Pierluigi
AU - Ferella, Letizia
AU - D'Angelo, Elisa
AU - Maddalo, Marta
AU - Alterio, Daniela
AU - Infante, Gabriele
AU - Bacigalupo, Almalina
AU - Argenone, Angela
AU - Iacovelli, Nicola Alessandro
AU - Desideri, Isacco
AU - Meduri, Bruno
AU - Triggiani, Luca
AU - Volpe, Stefania
AU - Belgioia, Liliana
AU - Dionisi, Francesco
AU - Romanello, Domenico Attilio
AU - Fallai, Carlo
AU - Miceli, Rosalba
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background: To report the long-term outcome of patients undergoing re-irradiation (re-RT) for a recurrent or second primary head and neck cancer (RSPHNCs) in seven Italian tertiary centers, while testing the Multi-Institution Reirradation (MIRI) recursive partitioning analysis (RPA) recently published. Methods: We retrospectively analyzed 159 patients. Prognostic factors for overall survival (OS) selected by a random forest model were included in a multivariable Cox analysis. To externally validate MIRI RPA, we estimated the Kaplan-Meier group-stratified OS curves for the whole population. Results: Five-year OS was 43.5% (median follow-up: 49.9 months). Nasopharyngeal site, no organ dysfunction, and re-RT volume <36 cm3 were independent factors for better OS. By applying the MIRI RPA to our cohort, a Harrell C-Index of 0.526 was found indicating poor discriminative ability. Conclusion: Our data reinforce the survival benefit of Re-RT for selected patients with RSPHNC. MIRI RPA was not validated in our population.
AB - Background: To report the long-term outcome of patients undergoing re-irradiation (re-RT) for a recurrent or second primary head and neck cancer (RSPHNCs) in seven Italian tertiary centers, while testing the Multi-Institution Reirradation (MIRI) recursive partitioning analysis (RPA) recently published. Methods: We retrospectively analyzed 159 patients. Prognostic factors for overall survival (OS) selected by a random forest model were included in a multivariable Cox analysis. To externally validate MIRI RPA, we estimated the Kaplan-Meier group-stratified OS curves for the whole population. Results: Five-year OS was 43.5% (median follow-up: 49.9 months). Nasopharyngeal site, no organ dysfunction, and re-RT volume <36 cm3 were independent factors for better OS. By applying the MIRI RPA to our cohort, a Harrell C-Index of 0.526 was found indicating poor discriminative ability. Conclusion: Our data reinforce the survival benefit of Re-RT for selected patients with RSPHNC. MIRI RPA was not validated in our population.
KW - head and neck cancers
KW - modern RT techniques
KW - overall survival
KW - re-irradiation
KW - toxicity
UR - http://www.scopus.com/inward/record.url?scp=85070311035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070311035&partnerID=8YFLogxK
U2 - 10.1002/hed.25890
DO - 10.1002/hed.25890
M3 - Article
C2 - 31355972
AN - SCOPUS:85070311035
VL - 41
SP - 3684
EP - 3692
JO - Head and Neck Surgery
JF - Head and Neck Surgery
SN - 1043-3074
IS - 10
ER -